In 189 adults with type 2 diabetes on diet and exercise alone, weekly cagrilintide-semaglutide cut HbA1c at 40 weeks vs placebo (−1·7 points at 2·4 mg each, −1·3 at 1·0 mg; both p<0·0001). Adverse events 79%/75% vs 66%, mostly gastrointestinal.
RCTn = 189
Aroda et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study